Marshall Wace, LLP Cassava Sciences Inc Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$21.59 - $27.88 $525,673 - $678,822	24,348 New	24,348 $597,000
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $2.57 Million - $8.03 Million	157,325 New	157,325 $6.58 Million
Q2 2021 Aug 13, 2021	SELL	$32.15 - $89.72 $6.3 Million - $17.6 Million	-195,942 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$7.09 - $87.95 $1.5 Million - $18.6 Million	-211,864 Reduced 51.95%	195,942 $8.81 Million
Q4 2020 Feb 16, 2021	BUY	$6.79 - $12.25 $2.63 Million - $4.75 Million	387,866 Added 1945.17%	407,806 $2.78 Million
Q3 2020 Nov 16, 2020	BUY	$2.86 - $11.51 $57,028 - $229,509	19,940 New	19,940 $230,000
Q1 2020 May 15, 2020	SELL	$3.26 - $9.65 $178,220 - $527,555	-54,669 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.1 - $6.12 $60,135 - $334,574	54,669 New	54,669 $284,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $110M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.